Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 17NIH 6OTHER_GOV 2UNKNOWN 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 30Capecitabine 26Fluorouracil 20Irinotecan 19tislelizumab 18apatinib 16Paclitaxel 13Cisplatin 13S 1 (combination) 12Radiotherapy 12Leucovorin 11Bevacizumab 11Laparoscopy 9Drug Therapy 9Cetuximab 9sintilimab 8Endoscopic Mucosal Resection 8Radiation 7Gemcitabine 7Docetaxel 7camrelizumab 6XELOX 6Surgical Procedures, Operative 6Propranolol 6Nivolumab 6Neoadjuvant Therapy 6Immune Checkpoint Inhibitors 6Folfox protocol 6Levoleucovorin 5HMPL-013 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Thalidomide × Gastrointestinal × Clear all
NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Henan Cancer Hospital

Phase 2 Unknown
132 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT05266820 2022-03-18

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Fujian Cancer Hospital

Phase 2 Unknown
120 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡